Pathogenic mutations in Leucine-rich repeat kinase 2 (LRRK2) are the predominant genetic cause of Parkinson's disease (PD) and often lead to increased kinase activity, making LRRK2 inhibitors promising treatment options. However, despite ongoing clinical trials, specific, sensitive, and non-invasive...
